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Abstract 
Recent studies have shown adjuvant properties of baculovirus by enhancing and modulating the immune response in mammals. 
This ability has been explained in part by the activation of the innate immunity. In addition, baculovirus induce a vigorous 
cytotoxic response characterized by a large number of IFNγ-producing cells. By flow cytometry analysis, we demonstrated that, 
when inoculated in mice, wild type baculovirus induce IFNγ and IL-12 expression and activation of NK and NKT cells.  
By manipulating baculovirus’ genome via homologous recombination it is possible to display multiple copies of heterologous 
polypeptides on the surface in a multimeric way. So, the same particle could act as both a multimeric antigen presentation 
structure and a potent adjuvant. As an effective immune response against tuberculosis infection is believed to primarily rely on 
the development of T helper 1 (Th1)-biased and cytotoxic responses, here we developed a recombinant baculovirus by 
engineering its genome in order to display polypeptide 85A from Mycobacterium tuberculosis on the surface of baculovirus. 
Thus, we combined the immunogenic advantages of baculovirus and the antigenic features of 85A antigen for the design of novel 
tuberculosis vaccine candidates.  
© 2009 Elsevier B.V. 
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The current vaccine against tuberculosis (TB), the bacille Calmette–Guérin (BCG), is an attenuated strain of 
Mycobacterium bovis. BCG protects against severe childhood forms of the disease, but fails to protect against adult 
pulmonary TB in countries in which it is endemic. For more than 80 years no new tuberculosis vaccines have 
successfully been developed. With tuberculosis eradication on the horizon, new vaccines with better protection than 
BCG are needed.  
An effective TB vaccine should have to elicit a greater immune response than that induced by natural infection. 
The goal is a new generation of effective vaccines against the respiratory forms of TB, which need to activate both 
CD4 and CD8 T cell responses to elicit protective immunity against M. tuberculosis. In fact, resistance to M. 
tuberculosis involves the activation of mycobacteria-specific CD4 and CD8 T cells by dendritic cells (DCs), which 
migrate from the site of infection in the alveoli to the draining lymph nodes. The development of IFNγ-secreting 
CD4 T cells depends on IL-12 secretion by infected DCs. Individuals deficient in receptors for IFNγ and IL-12 are 
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extremely susceptible to mycobacterial infections, confirming the absolute requirement of Th1 T cells for host 
immunity [Flynn et al., Tuberculosis 84(1-2):93, 2004]. Therefore, formulations that induce the production of 
enduring Th1 responses are desirable, and doubtless an essential element of a successful vaccine.  
Recent studies have shown adjuvant properties of baculovirus AcNPV (BV), which acts enhancing and 
modulating the immune response in mammals. This ability has been explained in part by the activation of the innate 
immunity. BVs exert these effects by a mechanism mediated principally by IFN-αβ, although type I IFN-
independent mechanisms are also involved [Hervas-Stubbs et al., J Immunol 174(4):2361, 2007]. By manipulating 
BVs genome via homologous recombination, it is possible to display multiple copies of heterologous polypeptides 
on the surface or in the inner capsid in a multimeric way. So, the same particle could act as a multimeric antigen 
presentation structure and as a potent adjuvant. A BVs displaying a circumsporozoite protein from Plasmodium 
falciparum [Yoshida et al., Virol 316(1):161, 2003] has shown to induce antibodies and a high frequency of IFNγ-
producing specific T cells in mice, and it is noteworthy that a strong cellular response specific to BVs has been also 
observed after re-stimulation in vitro.  
Several adjuvant or live vaccines against TB capable of inducing potent T-cell responses have been developed 
and some have entered clinical testing. The antigen 85A gene (fbpA) of M. tuberculosis delivered in recombinant 
vaccinia virus Ankara is one of the TB candidate vaccines that has entered phase I trials [Brennan et al., 
PlosMedicine 4(8):e252, 2007].
In this work we designed a new TB candidate vaccine by engineering the BV genome in order to display the M. 
tuberculosis 85A antigen on BVs surface. 
In order to evaluate the ability of BVs to induce an innate immune response we first studied the capture of BVs 
by DCs and the subsequent induction of their maturation. Different concentrations of a BV expressing GFP (BV-
GFP) were incubated with bone marrow-derivated cells (BMDCs) at 37 °C (Figure 1) for 2 h, stained with 
monoclonal antibodies to cell surface antigens, and analyzed by flow cytometry [FACScalibur (BD)] for cell surface 
marker expression. Incubation at 4°C was used as a control to test adsorption to BMDCs. As shown in Figure 1, 
endocytosis of BVs increased as multiplicity of infection (moi) did, indicating an efficient capture by DCs. The 
endocytic process was saturated when cells were incubated at 4°C with 104 plaque forming units (pfu) of BVs, 
where 90% of BMDCs showed a mean intensity of fluorescence of 50%.   
Then, the maturation of DCs by BVs was assessed by detection of surface activation markers, such as CD40 and 
CD86 and by the production of IL-12 p40 and IL6 by BMDCs. Cells were incubated with BVs for 18 h, stained with 
anti-CD86 and anti-CD40 and analyzed by flow cytometry. BVs upregulated the expression of CD40 and CD86 in 
DCs as well as the production of IL-12 p40 (11 ng/ml vs 1 ng/ml basal) and IL-6 (180 pg/ml vs 50 pg/ml basal) 
compared to the controls, BMDCs incubated with PBS. Therefore, these results showed that BVs induced 
maturation of DCs after their in vitro uptake.  
The development of effective adaptive immune responses depends on the induction of an innate immune 
response. Therefore, we investigated the stimulation of innate immune responses by BVs in mice. Female BALB/c 
mice were immunized by i.v. injection with BVs and the production of IFNγ and IL-12 p40 in serum was 
determined by ELISA 6 h post infection (hpi). Low levels of IFNγ were detected in animals inoculated with 200 µl 
of supernatants from uninfected Sf9 cells, whereas high levels of IFNγ (8 ng/ml vs 0,05 ng/ml basal) and IL-12 p40 
(700 pg/ml vs 300 pg/ml) were detected in sera from animals injected with the same volume of supernatants from 
BV-infected Sf9 cells (BV dose: 5 x 107pfu) (data not shown), showing that the in vivo production of IFNγ and IL-
12 p40 was due to BVs and not to Sf9 cell contaminants. 
Paula Molinari et al. / Procedia in Vaccinology 1 (2009) 81–84 83
Figure 1. In vitro capture of BVs by BMDCs and induction of maduration. BV-GFP capture was analyzed in BMDCs 
incubated with different moi of BV-GFP (pfu of BV-GFP/number of BMDCs) for 2 h, labeled with an anti-CD11c antibody and 
analyzed by flow cytometry. Mean intensity of fluorescence (MIF) of BMDCs (A) and percentage of BMDCs GFP+ (B). The 
maturation of BMDCs induced by BVs was analyzed by incubation of BMDCs with 3.3 x 106 pfu/ml of BVs for 18 h. 
Phenotypic activation markers CD40 and CD86 were evaluated on BMDCs and analyzed by flow cytometry (C). 
Kitajima and colleages have recently found that BVs infect DCs and induce NK cell-dependent antimetastatic 
effects in mice [Kitajima et al., Clin Vaccine Immunol 15(2):376, 2008]. Based on this finding, we hypothesized 
that the IFNγ detected in sera from mice inoculated with BVs was produced by NK and NKT cells. In order to 
evaluate this presumption, we determined the production of these cytokines in NK and NKT by intracellular staining 
and flow cytometry analysis. Our results showed high IFNγ production by NK and NKT cells, indicating the in vivo
activation of these cell populations by BVs (Figure 2). 
Next, we investigated whether BVs could induce DCs maturation in vivo. For this purpose, splenic conventional 
DCs (cDCs) obtained from BALB/c mice previously injected with PBS or BVs were analyzed for the presence of 
the phenotypic activation marker CD86 (cDC-CD11c) by flow cytometry analysis. BVs strongly activated cDCs in 
vivo, as showed by the five times increased expression of CD86 in DCs from mice inoculated with BVs compared to 
that of control animals (data not shown). This result was similar to that obtained by Hervas-Stubbs et al [Hervas-
Stubbs et al., J Immunol 174(4):2361, 2007]. 
Taking together, these results demonstrated that BVs were captured by DCs, inducing their maturation and a 
strong innate immune response with high levels of IFNγ production. However, the precise mechanism by which 
BVs exert their adjuvant effects remains unclear.  
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In order to combine the adjuvancy of BVs and the antigenic properties of 85A antigen, a recombinant BV bearing 
85A was generated following the procedure described in Peralta et al. [Peralta et al., Appl Microbiol Biotechnol 
75(2):407, 2007]. A DNA fragment encoding the full length fbpA was inserted into pVL1393Sup vector to express a 
85A–GP64 fusion protein on the virion surface and the expression of the recombinant fusion protein was 
demonstrated by Western blot of cell extracts infected with BV-85Sup using a specific polyclonal antibody (data not 
shown). As a control, a BV overexpressing GP64 (BV-GP64Sup) from a second copy of gp64 gene inserted in the 
polyhedrin locus was used. Once the expression of the recombinant proteins was confirmed (data not shown), 
budded viruses were purified from sucrose cushions, separated in a 10% SDS-PAGE and transferred to a 
nitrocellulose membrane to determine the correct incorporation of the 85A-GP64 fusion into the viral particle. 
Western blots of purified viruses revealed with both anti-85A and anti-GP64 (monoclonal antibody AcV5) 
antibodies showed that viral extracts exhibited a major reactive band of about Mr 98,000, which is in the range of 
the expected molecular weight for this fusion protein, and no bands were detected in control viruses (BV-GP64Sup). 
An additional band was detected with AcV5 antibody at Mr 64,000, which represents the wild type copy of GP64 of 
the BV-GP64Sup. The presence of 85A-GP64 fusion on the budded BVs did not alter viral infectivity, as 
recombinant virus routinely exhibited high titers, similar to those obtained with wild type BVs. 
In conclusion, these data demonstrate that BVs are involved in the generation of innate immune responses 
inducing IFNȖ production from NK and NKT cells. By in vitro assays we demonstrate that BVs are captured by DCs 
inducing their maturation and that the recombinant BV-85ASup can display the 85A antigen as a fusion to GP64 on 
its surface. 
Finally, the results obtained in this study highlight the use of BVs vector for antigen presentation and as 
immunopotentiator of cell-mediated immune responses. 
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IFNγ by NK and NKT. BALB/c 
mice were injected with 5 x 107pfu 
BVs or PBS via i.v. and 3 h post 
immunization splenocytes were 
incubated for 3 h with brefeldin A,
stained with anti-CD3 (clone 17A2) 
and anti-CD49b (clone DX5), 
intracellularly stained with anti-IFNγ
(clone XMG1.2) and analyzed by 
flow cytometry.  
Figure 3. Expression of recombinant fusion 
proteins in BVs. Supernatants of Sf9 cells 
infected either with BV-85ASup (lane 1),  BV-
GP64Sup (lane 2) or Sf9 cells uninfected were 
harvested 5 dpi, ultracentrifuged, resuspended in 
loading buffer, and subjected to electrophoresis 
on 0.1% SDS–10% polyacrylamide gels.
Western blots were revealed with a polyclonal 
antibody to 85A (left panel) or a monoclonal 
antibody to GP64 (right panel).  
1       2       3        1       2        3
Anti-85A              Mab-gp64 
85A-GP64
GP64
